Connect with us

Hi, what are you looking for?


Is it too late to invest in the Biotech stocks?

“IBB” – the iShares Biotechnology ETF has already recovered about 30% over the past five months but Jefferies’ Michael Yee is convinced it still has more room to the upside.

Yee’s bull case for the biotech stock

Yee sees several catalysts that could potentially push these stocks further up in the coming months.

To begin with, biotech had a strong third quarter and more importantly, notable names in this space raised their guidance as well. That signals continued strength. Yee is also bullish because:

The visibility on cancer drugs and new diabetes drugs and new obesity drugs is pretty [clear] over the next twelve months. So, we think it’s been a great place to be, but we still think there’s more to go.

On top of that, inflation seems to be coming down as Invezz reported here. In response, if the Fed chooses to “pause”, it will create a better macroeconomic environment for the biotech stocks as well.

Biotech stocks are still not expensive

Versus the start of 2022, IBB is still down more than 10%.

And that makes up for another reason why Yee recommends investing in this exchange-traded fund. On CNBC’s “Power Lunch”, he said:

These stocks were super cheap. Even though they’re up 30% to 40% off the bottom, they’re still not expensive. So, we still think there’s room to go.

In terms of individual names, he’s particularly bullish on the likes of Gilead Sciences Inc (NASDAQ: GILD) that’s still trading well below the average of its price-to-earnings ratio for the past five years.

The post Is it too late to invest in the Biotech stocks? appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Reprinted from the Future of Freedom Foundation President Biden’s campaign to banish (or maybe outlaw) political paranoia took a wallop last spring. In April,...


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...

    Editor's Pick

    It’s already a cliché, but technology is rapidly improving. And for many businesses, it’s hard to catch up. However, it’s not just the average...

    Editor's Pick

    At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.